悦康药业YKYY013注射液获得FDA临床试验批准

Core Viewpoint - YKYY013 injection, developed by Yuyuan Pharmaceutical's subsidiary, has received FDA approval for clinical trials targeting chronic hepatitis B virus infection [1] Company Summary - Yuyuan Pharmaceutical's subsidiary, Beijing Yuyuan Kete Pharmaceutical Technology Co., Ltd., is responsible for the development of YKYY013 injection [1] - The injection is a chemically synthesized double-stranded siRNA drug that utilizes N-acetylgalactosamine (GalNAc) as a ligand [1] - The drug aims to silence the HBV genome transcription messenger RNA through RNA interference, thereby inhibiting the production of hepatitis B pathogen proteins and HBV replication [1] Industry Summary - The clinical application of YKYY013 injection is focused on treating chronic hepatitis B virus infections [1] - The drug is designed to create conditions for host immune reconstitution, ultimately aiming for functional cure of hepatitis B [1]